Search

Government reduces price of 390 Anti-Cancer Non-Scheduled Medicines upto 87 percent

This move is expected to benefit 22 lakh cancer patients in the country and would result in annual savings of around Rs. 800 crores to the consumers.

Mar 9, 2019 13:25 IST
facebook IconTwitter IconWhatsapp Icon

The National Pharmaceutical Pricing Authority (NPPA), under the Union Ministry of Chemicals & Fertilizers on March 8, 2019 announced the reduction in prices of 390 Anti-Cancer Non-Scheduled Medicines up to 87 percent.

The revised prices of these anti-cancer drugs would come into effect from March 8, 2019 itself.

The authority directed the manufacturers and hospitals to convey revised prices of the medicines based on the Trade Margin (TM) formula.  

These 390 anti-cancer drugs brands, which make up about 91 percent of the 426 brands reported by manufacturers, showed downward price movement.

Note

Non-scheduled drugs are allowed an increase of up to 10 percent in prices every year, which is monitored by the National Pharmaceutical Pricing Authority (NPPA).

Significance

The average out of pocket expenditure of cancer patient is 2.5 times more than that of other diseases.

This move is expected to benefit 22 lakh cancer patients in the country and would result in annual savings of around Rs. 800 crores to the consumers.

Previous similar move by NPPA

Earlier on February 27, 2019, the NPPA had put 42 anti-cancer drugs under 30 percent Trade Margin cap. 

The Trade Margin rationalisation for 42 anti cancer drugs was rolled out as Proof of Concept, stressing on the new standard of self-regulation by the Industry.  The manufacturers of these 42 drugs were directed not to reduce production volumes of brands under regulation.

Download our Current Affairs & GK app For exam preparation

डाउनलोड करें करेंट अफेयर्स ऐप एग्जाम की तैयारी के लिए

AndroidIOS